Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697216 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL21392956 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL22990581 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL21376540 | 0.93 | ALDH1A1 (0.55) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL18963575 | 0.93 | ALDH1A1 (0.55) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL21393208 | 0.93 | KDM4E (0.58) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL21393042 | 0.92 | KDM4E (0.57) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL26196576 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL18963691 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1LMNAALBMAPK1 | |
| SCHEMBL31093232 | 0.88 | KDM4E (0.67) | KDM4EALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4137499-A1 | 7-SUBSTITUTED 7-DEAZAADENINE-CONTAINING 2,3 -CYCLIC DINUCLEOTIDES | Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) | 2023-02-22 | — | — | EP | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022125984-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| EP-3936514-A1 | 3'3' CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. (CZ) | 2022-01-12 | — | — | EP | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| EP-3922637-A1 | MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES | Janssen Pharmaceutica NV (BE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20030212032-A1 | Acid resistance, stability; telomerase inhibitor | GERON CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6608036-B1 | Inhibit telomerase enzyme activity; inhibit proliferation of cell that expresses telomerase | GERON CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | GERON CORPORATION | 2003-07-24 | — | — | US | disclosed |
| CN-1415622-A | Method for preparing 6-alkoxy-2',3'-double deoxidated guanosine | CHANGAO SCIENCE AND TECHNOLOGY (CN) | 2003-05-07 | — | — | CN | disclosed |
| WO-2002077184-A2 | OLIGONUCLEOTIDE CONJUGATES | GERON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1210357-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE | Geron Corporation (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001018015-A1 | OLIGONUCLEOTIDE N3'→P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE | GERON CORPORATION (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-0640091-A4 | SYNTHESIS OF NUCLEOTIDE MONOMERS. | RIBOZYME PHARM INC (US) | 1995-07-26 | — | — | EP | disclosed |
| EP-0640091-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023413-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | KDM4E 2160/4885ALDH1A1 4763/4885LMNA 2609/4885 |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | TERT, RNGTT, DUT | KDM4E 1823/4885ALDH1A1 518/4885LMNA 632/4885 |
| US-20030212032-A1 | Acid resistance, stability; telomerase inhibitor | NT5C3B, MTAP, TERT | KDM4E 3093/4885ALDH1A1 2661/4885LMNA 3317/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | KDM4E 2160/4885ALDH1A1 4763/4885LMNA 2609/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | KDM4E 2160/4885ALDH1A1 4763/4885LMNA 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.